Tariq Shah, MD
Nephrology · Los Angeles, CANPI 1750452116
Payments from drug & device makers
Across 481 payments — averaging $2441.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$786K
- Sanofi$138K
- Mallinckrodt Hospital Products Inc.$53K
- Mallinckrodt Enterprises LLC$52K
- Apellis Pharmaceuticals, Inc.$31K
- Sanofi-aventis U.S. LLC$26K
- plus $88K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 61 | $785,574 |
| Sanofi | 99 | $138,489 |
| Mallinckrodt Hospital Products Inc. | 39 | $53,229 |
| Mallinckrodt Enterprises LLC | 43 | $52,061 |
| Apellis Pharmaceuticals, Inc. | 23 | $30,964 |
| Sanofi-aventis U.S. LLC | 19 | $25,967 |
| Veloxis Pharmaceuticals, Inc. | 43 | $25,204 |
| AbbVie(2 entities) | 2 | $17,448 |
| E.r. Squibb & Sons, L.L.C. | 2 | $14,651 |
| Novartis | 24 | $7,687 |
| Boehringer Ingelheim | 10 | $5,693 |
| Pfizer | 1 | $5,050 |
| Lilly USA, LLC | 9 | $3,556 |
| Amgen(2 entities) | 32 | $2,940 |
| Calliditas Therapeutics US Inc. | 13 | $2,903 |
| AstraZeneca(2 entities) | 11 | $374 |
| Ardelyx, Inc. | 11 | $367 |
| OPKO Pharmaceuticals, LLC | 7 | $310 |
| Travere Therapeutics, Inc. | 4 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $228 |
| Bayer | 8 | $207 |
| ANI Pharmaceuticals, Inc. | 2 | $186 |
| Novo Nordisk | 3 | $169 |
| Biogen | 1 | $149 |
| GSK | 2 | $134 |
| Merck | 1 | $121 |
| Fresenius USA Marketing, Inc. | 1 | $102 |
| Otsuka America Pharmaceutical, Inc. | 2 | $78 |
| Vifor Pharma, Inc. | 2 | $43 |
| La Jolla Pharmaceutical Company | 1 | $42 |
| Smith+Nephew | 1 | $14 |
How this compares
$1,174,173 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.